Marc Schegerin

Marc Schegerin, MD, is Chief Financial Officer and Chief Operating Officer of Morphic. Dr. Schegerin has extensive experience in the biotechnology space spanning clinical and business development, strategy, finance and operations. Most recently, Dr. Schegerin served as chief financial officer, treasurer and head of strategy & communications at ArQule, an oncology-focused drug developer, until its acquisition by Merck. Prior to this role, Dr. Schegerin served in various senior healthcare investment banking roles at CitiGroup and Bank of America Merrill Lynch. Dr. Schegerin has also held industry management roles at Biogen and Sage Therapeutics and began his career in the healthcare group at Goldman Sachs. Dr. Schegerin earned his MD from Dartmouth Medical School and MBA from the Tuck School of Business at Dartmouth and undergraduate degrees in premedical studies from Harvard University and finance from Tulane University.